Supreme Court Report

Supreme Court of the United States · Official docket →

Mylan Pharmaceuticals Inc., et al. v. UCB, Inc., et al.

Paid petition · United States Court of Appeals for the Federal Circuit, No. 2016-2610, 2016-2683, 2016-2685, 2016-2698, 2016-2710, 2017-1001 · judgment May 23, 2018

Certiorari denied · February 19, 2019
Pre-decision estimate: 2% cert probability

Before the decision, well below the 4.1% base rate, with no standout signals pointing toward a grant.

Question presented

{ ADDITIONAL COUNSEL FOR THE PETITIONERS } CHARLES B. KLEIN TODD S. WERNER WINSTON & STRAWN LLP CARLSON, CASPERS, 1700 K STREET, N.W. VANDENBURGH & LINDQUIST P.A. WASHINGTON, DC 20006 225 SOUTH SIXTH STREET,

  1. 282-5000 SUITE 4200 CKLEIN@WINSTON.COM MINNEAPOLIS, MN 55402

  2. 436-9600 TWERNER@CARLSONCASPERS.COM

Counsel of record

For petitioner
David Sidney Steuer
Wilson, Sonsini, et al.

For respondent
Ian Scott
Taft Stettinius & Hollister, LLP

Case

Conference history
Distributed for 1 conference

Amicus briefs
3 cert-stage

Proceedings

  1. Feb 19 2019
    Petition DENIED.
  2. Jan 09 2019
    DISTRIBUTED for Conference of 2/15/2019.
  3. Dec 27 2018
    Brief amicus curiae of Association for Accessible Medicine filed.
  4. Dec 27 2018
    Brief amicus curiae of America’s Health Insurance Plans filed.
  5. Dec 26 2018
    Waiver of right of respondents UCB, Inc., et al. to respond filed.
  6. Dec 24 2018
    Blanket Consent filed by Respondents, Apotex Corp. and Apotex, Inc..
  7. Dec 21 2018
    Brief amici curiae of R Street Institute and Public Knowledge filed.
  8. Dec 17 2018
    Blanket Consent filed by Petitioners, Mylan Pharmaceuticals Inc., et al..
  9. Nov 21 2018
    Petition for a writ of certiorari filed. (Response due December 27, 2018)